Company intelligence / Profile preview
ProLynx Inc.
San Francisco, California, United Statesprolynxinc.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ProLynx has demonstrated in preclinical studies that its platform can extend the dosing interval of peptide drugs such as semaglutide from once weekly to once monthly while maintaining efficacy. For example, a single injection of their long‑acting semaglutide led to ~20% weight loss over 30 days in obese mice—comparable to multiple standard injections. The company’s technology has also been applied to other peptides and proteins for half-life extension and improved pharmacokinetics.
- Therapeutic areas
- GastroenterologyOncologyEndocrinology
- Modalities
- Peptidesproteinssmall moleculesrecombinant proteinssynthetic peptides
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Institut Curiecollaborations with academic institutions and pharmaceutical companies for development/licensing of conjugates/platform applications
Beyond the preview
Go deeper on ProLynx Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProLynx Inc..